Montag & Associates’s BeOne Medicines Ltd ONC Stock Holding History

Montag & Associates’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Hold	750	–	–	0.01%	413
2026 Q1	$223K	Hold	750	–	–	0.01%	404
2025 Q4	$228K	Hold	750	–	–	0.01%	393
2025 Q3	$256K	Hold	750	–	–	0.01%	369
2025 Q2	$182K	Sell	750 -250	-25%	-$61.3K	0.01%	411
2025 Q1	$272K	Hold	1,000	–	–	0.01%	379
2024 Q4	$185K	Hold	1,000	–	–	0.01%	433
2024 Q3	$225K	Hold	1,000	–	–	0.01%	413
2024 Q2	$143K	Hold	1,000	–	–	0.01%	447
2024 Q1	$156K	Hold	1,000	–	–	0.01%	438
2023 Q4	$180K	Hold	1,000	–	–	0.01%	411
2023 Q3	$180K	Hold	1,000	–	–	0.01%	395
2023 Q2	$178K	Hold	1,000	–	–	0.01%	405
2023 Q1	$216K	Hold	1,000	–	–	0.01%	377
2022 Q4	$220K	Hold	1,000	–	–	0.01%	352
2022 Q3	$135K	Hold	1,000	–	–	0.01%	403
2022 Q2	$162K	Hold	1,000	–	–	0.01%	386
2022 Q1	$189K	Hold	1,000	–	–	0.01%	395
2021 Q4	$271K	Hold	1,000	–	–	0.01%	358
2021 Q3	$363K	Hold	1,000	–	–	0.02%	319
2021 Q2	$343K	Hold	1,000	–	–	0.02%	330
2021 Q1	$348K	Hold	1,000	–	–	0.02%	323
2020 Q4	$258K	Buy	+1,000	New	+$275K	0.02%	332

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Montag & Associates's ONC Position: Q2 2026 in Review

Montag & Associates held its BeOne Medicines Ltd (ONC) position steady in Q2 2026 at 750 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #413.

Montag & Associates first reported a position in ONC in Q4 2020 and has held it in 23 quarters since. The position peaked at $363K in Q3 2021. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Montag & Associates held 750 shares of BeOne Medicines Ltd worth $214K as of Q2 2026.
Montag & Associates left its BeOne Medicines Ltd share count unchanged in Q2 2026.
BeOne Medicines Ltd made up 0.01% of Montag & Associates's portfolio in Q2 2026, its #413 holding.
Montag & Associates first reported a position in BeOne Medicines Ltd in Q4 2020 and has held it in 23 quarters since.
Montag & Associates's BeOne Medicines Ltd position peaked at $363K in Q3 2021.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.